8月7日,礼来公布其备受瞩目的口服GLP-1小分子激动剂Orforglipron的III期临床数据,结果却出人意料。尽管试验在统计学上达到了主要终点,但市场对其疗效的期待落空,礼来股价在盘前交易中遭遇重挫,市值瞬间蒸发约500亿美元。截至发稿,美股开盘,礼来股价跌破700美元大关,下跌约15%。图片来源:腾讯微证券Orforglipron作为全球首个进入III期临床的口服小分子GLP-1受体激动剂...
Source Link8月7日,礼来公布其备受瞩目的口服GLP-1小分子激动剂Orforglipron的III期临床数据,结果却出人意料。尽管试验在统计学上达到了主要终点,但市场对其疗效的期待落空,礼来股价在盘前交易中遭遇重挫,市值瞬间蒸发约500亿美元。截至发稿,美股开盘,礼来股价跌破700美元大关,下跌约15%。图片来源:腾讯微证券Orforglipron作为全球首个进入III期临床的口服小分子GLP-1受体激动剂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.